RESUMO
Objective To evaluate smooth muscle protein of 22 kDa (SM22) in the diagnosis of acute intestinal ischemia.Methods 96 healthy adult SD rats were evenly divided into experimental group and control group,with each group subdivided into 6 subgroups,subject respectively to superior mesenteric artery ligation or sham operation.The venous blood samples were extracted from each group rats' right heart atO.5,1,2,4,8,12 h after the operation,for SM22 testing and small intestines tissues for direct immunofluorescence staining of SM22.Results The serum SM22 concentration reached a peak at 4 h (265 ± 15) mg/L,then gradually decreased (P ＜ 0.05).The I-FABP was mainly expressed in the epithelium of intestinal mucosa.During the 4 hours of intestinal ischemia,The number of SM22 positive particles did not change.After 4 hours,the number of SM22 positive granules had gradually decreased compared with the control group (all P ＜ 0.05).Conclusion SM22 mainly exists in the smooth muscle of intestinal,during the ischemic necrosis of the intestinal muscle layer SM22 leaks into blood stream,resulting in high serum levels of SM22 facilitating early diagnosis of acute intestinal ischemia.
RESUMO
Objective To explore the feasibility and clinical value of metallic stent in the management of unresectable hepatic portal cholangiocarcinoma. Methods A study was investigated in 17 patients with unresectable hepatic portal cholangiocarcinoma from January 1998 to January 2006. A memory alloy biliary stent was placed into the obstructive bile duct for internal biliary drainage. Results Patients’ jaundice disappeared within 2 weeks after the stent placement. Cholangiography via the drainage tube showed patent bile ducts. Follow-up surveys in 16 patients for 4~30 months (mean, 11.5 months) revealed a survival time of 4~20 months (mean, 11 months) in 13 fatal patients. The remaining 3 patients had survived 10, 12.5, and 30 months, respectively. Conclusions Placement of memory metallic biliary stent for patients with unresectable hepatic portal cholangiocarcinoma is an ideal palliative therapy, which is simple and effective for reducing jaundice.